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Abstract
Background: The current state of the art for measuring stromal response to targeted therapy requires
burdensome and rate limiting quantitative histology. Transcriptome measures are increasingly affordable and
provide an opportunity for developing a stromal versus cancer ratio in xenograft models. In these models, human
cancer cells are transplanted into mouse host tissues (stroma) and together coevolve into a tumour
microenvironment. However, profiling the mouse or human component separately remains problematic. Indeed,
laser capture microdissection is labour intensive. Moreover, gene expression using commercial microarrays
introduces significant and underreported cross-species hybridization errors that are commonly overlooked by
biologists.
Method: We developed a customized dual-species array, H&M array, and performed cross-species and species-
specific hybridization measurements. We validated a new methodology for establishing the stroma vs cancer ratio
using transcriptomic data.
Results: In the biological validation of the H&M array, cross-species hybridization of human and mouse probes was
significantly reduced (4.5 and 9.4 fold reduction, respectively; p < 2x10-16 for both, Mann-Whitney test). We
confirmed the capability of the H&M array to determine the stromal to cancer cells ratio based on the estimation
of cellularity index of mouse/human mRNA content in vitro. This new metrics enable to investigate more efficiently
the stroma-cancer cell interactions (e.g. cellularity) bypassing labour intensive requirement and biases of laser
capture microdissection.
Conclusion: These results provide the initial evidence of improved and cost-efficient analytics for the investigation
of cancer cell microenvironment, using species-specificity arrays specifically designed for xenografts models.
Background
In spite of developments in high throughput molecular
assessment biotechnologies, it remains particularly chal-
lenging to investigate molecular expression in the tumor
microenvironment containing local tumor stoma, reactive
stromal cells and cancer cells. There is increasing evidence
that the development and progression of cancer is signifi-
cantly affected by interactions between the tumor and its
microenvironment [1-6], suggesting that the ability to pro-
file gene expression in both stromal and cancer cell com-
partments is critical. Malignant tumors are composed of
cancer cells and their associated host cells, which include
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blood and lymph endothelial cells, immune cells, fibro-
blasts and myofibroblasts [7,8]. The host cells, also termed
stromal cells here, make up about half of most malignant
tumors [9] and have emerged as targets of anti-tumor
therapy in recent years [10].
Currently, the best way to selectively isolate cancer cells
from a heterogeneous population of cells in a tumor is
Laser Capture Microdissection (LCM) [11]. While LCM is
increasingly used in the selection of cancer cells [12-14],
the application of LCM to stromal masses presents several
important technical challenges: (i) some cell types (e.g.
endothelial cells) are too long and thin or intertwined with
cancer cells to be isolated due to their infiltrating growth
and (ii) the visualization of samples and accurate determi-
nation of cell type can be difficult because cellular staining
via immunochemistry is not compatible with array ana-
lyses [10]. Furthermore, LCM of large numbers of cells
from many sections and samples is rate limiting and cum-
bersome, requiring a considerable amount of time (1 day/
sample) and sub-zero temperatures. Therefore, novel and
affordable high throughput approaches are required to
assess the expression of cancer and stromal cells to deter-
mine their molecular interactions. Further, transcriptome
measures from RNA-seq or conventional expression arrays
present the opportunity to develop in silico estimates of
cancer cells versus stromal cell ratios, which otherwise
require labour intensive quantitative histology measures
across hundreds of microscopic fields per tissue sample.
Xenograft models, where human cancer cells are grown
in immunodeficient mice, are popular for studying the
tumor microenvironment. In such models, the genes of
the stromal compartment and cancer cells come from
distinct species: mouse and human respectively. While
gene expression profiles of human cancer and mouse
stroma have been analysed by human microarrays [15],
this approach is limited because the human and mouse
genomes are highly homologous and commercially avail-
able arrays are not designed for simultaneously measur-
ing both mouse and human mRNAs [16]. Thus, the
interpretation of transcriptome intensities is confounded
by Cross-Species Hybridization (CSH), which we have
biologically confirmed to exist between human array
probes with universal mouse RNAs [17]. We also pre-
dicted that this CSH in xenograft models would preferen-
tially occur among homologous human-mouse genes in
human arrays resulting in combined gene expression sig-
nals where deregulated mouse stromal genes are jointly
measured along with human cancer genes [17]. We pre-
viously hypothesized that deregulated probes on human
arrays exposed to whole xenograft tissue experiments
could be mined to identify those probes most likely har-
bouring human-mouse CSH (due to homologous genes
and alternative non-homology factors), and that we could
impute the enrichment of biological processes and
molecular functions of stromal mechanisms via these
CSH probes using Gene Ontology (GO) gene set annota-
tions [17]. While many probes of homologous genes can
be enriched for a GO signal, a limitation of this previous
study is that this geneset-based approach is not designed
to impute differential expression of individual mouse
stromal genes. There is thus a need for improved species
specificity of probes in newer arrays designed specifically
for jointly studying stromal and cancer cell gene expres-
sion in xenograft models.
In many tumor biology and pharmacology xenograft stu-
dies, the interplay and co-expression patterns of cancer
and stromal cell genes need to be studied using the simul-
taneous analysis of both species in the same array experi-
ment. When tissue expression is detected using separate
mouse and human arrays, comparing mouse and human
gene expression requires complex and artefact-inducing
normalization of the two datasets. Currently, there is no
genome-wide dual-species microarray available. While
whole transcriptome RNA-sequencing (RNA-seq) of xeno-
graft models provides an elegant alternative, the problem
of disambiguating the expression intensities of homologu-
ous genes remains (though the solution is quite different:
an ambiguous RNA assembly problem). There exist two
published dual-species partial arrays, in which one con-
tains a mere 516 human probe-sets and 456 mouse probe-
sets [16] and a second contains only protease and inhibitor
genes [18]. Previously, we reengineered the process of
microbial diagnosis by designing a Panmicrobial array that
contained 9,477 species specific probes (SSPs) to address
1,710 distinct vertebrate viruses [19-21]. Drawing from
this experience, we hypothesized that we could establish a
comprehensive map of CSH in human and mouse arrays.
We thus designed the first genome-wide human-mouse
dual-species array (H&M array) for comprehensively
investigating gene expression of stromal. Furthermore, we
also hypothesised that this new dual species array would
allow for the development of a novel estimation of the
stroma/cancer cell ratio via a cellularity index based on
SSPs of homologous housekeeping genes as an alternative
to traditional histological LCM assessments. Here we
report the first genome-wide dual species array for human
and mouse gene expression in xenograft models and iden-
tify novel biological functions for CSH probes, that until
now have been misattributed to either human cancer cells
or mouse stromal cells.
Methods
Datasets and custom human-mouse whole genome arrays
used in this study
Microarray data from the two in vitro experiments
(Table 1) are available in the GEO repository under acces-
sion number GSE23377 (initial in vitro biological experi-
ment: GSE23054, version 1 GEO platform: GPL10714; in
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vitro validation experiment for CSH and stroma cell
ratio estimation: GSE23364, version 2 GEO platform:
GPL10749, Agilent Custom Array Order #023265). We
used nine genomic datasets to compute human-mouse
CSH (Additional file 1- Supp. Table S1). The list of
housekeeping mouse genes was previously published
[22,23] and the list of homologous mouse-human genes
was downloaded from NCBI (ftp://ftp.ncbi.nih.gov/pub/
HomoloGene) on Feb, 2009 (Build 63). By design, these
experiments generated Datasets S1, S2 and S3 that we
provide for reuse by other groups at http://lussierlab.org/
publications/HsMm_array
H&M array design, annotation, and analysis (Figure 1:
panels A-C)
As shown in Figure 1, the experimental design consists
first of an assemblage of the two sets of 44k probes based
on Agilent’s commercial human array and mouse array.
Agilent also provided cross hybridizing estimates between
mouse probes and human mRNAs and vice versa (7141
human and 6420 mouse probes; Datasets S2, S3), which
are redesigned to correct for comprehensive CSH. We
designed two custom arrays: the second and final one
improved on the original design after biological validation.
The H&M arrays contain all legacy probes from the com-
mercial human and mouse arrays as well as the newly
designed ones (Figure 1, panel A). The second and final
custom H&M array is identified as “H&M array version 2”
(Agilent GEO platform: GPL10749; Agilent Custom
Array Order #023265). In an initial in vitro biological
experiment, we cross-hybridize H&M array version 1 with
mouse mRNAs, human mRNAs, and a combination of
both human and mouse RNAs (Figure 1, Step B1; Table
1). We also conduct a parallel and extensive BLASTn ana-
lysis of potential cross species hybridization of probes
(Step B2). Taken together the biological and the computa-
tionally derived cross hybridizations serve as a model for
CSH propensity of probes, and have an extensive optimi-
zation method (Step B3). As shown in panel B of Figure 1,
we conduct a second iteration of probe design (Step B4),
and produce version 2 of the H&M array. A second and
more comprehensive biological experiment that cross
hybridizes six arrays (H&M array version 2) with mouse
and human mRNAs is used for the final evaluation (Step
B5; Table 1) and improved the annotation of the CSH of
each probe (Datasets S2, S3). Gene Ontology enrichment
studies are also performed and show rectification of the
cross-hybridization and validation of cellularity ratios
(Figure 1, panel C).
Step B1: initial cross-hybridization experiment of H&M
array version 1
As shown in Table 1, each channel of the two H&M arrays
is cross-hybridized producing four readouts. Biological
experiments are conducted to produce physical evidence
of human-mouse cross-hybridization and are designed to
identify CSH by independently arraying mouse mRNAs
and human mRNAs (in the red channel) against the joint
human and mouse probes of the dual-species array. Using
dual channel technology (measuring two groups of mRNA
labelled with different colors simultaneously on the same
array), we also pool human and mouse mRNA in equal
parts as a control on the green channel.
We first obtain human and mouse universal reference
RNAs from ArrayIt (Sunnyvale, CA), which were derived
from a homogenate of all tissues from the organism, mak-
ing them somewhat representative of any cell type. This
universal RNA is amplified and labelled according to the
Agilent Low RNA input Fluorescent Linear Amplification
Kit protocol and according to Agilent’s two-color quick
amp labelling protocol. The two arrays are scanned with
5 µm resolution and 100% power gain at 600PMT for
both Cy3 & Cy5 using the GenePix 4000B Axon Scanner.
We quantify gene expression values using Agilent Feature
Extraction Software and subtract the adjusted background
for each probe from the mean expression value. Finally,
we use an inclusion criterion to identify the probes that
show some RNA binding where the minimum expression
Table 1 Cross-species hybridization experiments for H&M array
Initial experiment**
Dual channel array 1 2
Exposed to RNA in red channel 1.5ug Hs* RNA (sample 1) 1.5ug Mm* RNA (sample 2)
Exposed to RNA in green channel 0.75ug Hs* RNA + 0.75 Mm* 0.75ug Hs* RNA + 0.75 Mm*
Array design Agilent 2x105k arrays
Validation experiment
Single channel array 1 2 3 4 5 6
Exposed to RNA human human human mouse mouse mouse
Array design 46k Human probes and 46k mouse probes
*Hs: Homo Sapiens, Mm: Mus Musculus
**In the initial experiment, two human-mouse dual-species arrays were custom printed on Agilent 2x105k arrays. Each array contained only one species of
universal mRNAs on the red channel (either human or mouse) and had a control sample containing equal quantities of universal human and mouse mRNAs on
the green channel.
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Figure 1 Schematic diagram for the biological and computational design and annotation of the H&M microarray. The whole array
design and analysis includes three stages, as described in the Materials and Methods Section. There were 3.6k newly designed probes in step A
and 7.1k newly designed probes in step B. All probes on H&M (Agilent GEO platform GPL10749) were optimally and extensively annotated for
cross-species hybridization as shown in Dataset S1. The Agilent pre-annotated cross-species hybridization probes from step A are given in
Datasets S2-3, and the processes used to design the new probes in version 1 were previously published [17].
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intensity has to be larger than a value of “1” when exposed
to the pooled human and mouse RNA in both arrays. This
threshold was set because when the expressed intensity was
less than 1, probes vary widely across the two experimental
repeats using the same quantity of pooled human and
mouse RNAs.
Step B2: BLASTn analysis of cross species hybridization in
array probes
The Basic Local Alignment Search Tool (BLAST) algo-
rithm [24] is run with default parameters to theoretically
predict the possibility of CSH for each probe by compar-
ing human array probes with mouse RNAs, and mouse
array probes with human RNAs. BLASTn was used
because of its ability to find “fuzzy” alignments to related
nucleotide sequences from other organisms. The hits are
ranked by their BLASTn score of which the highest
scoring hit is recorded, together with (i) the length of the
alignments and (ii) the number of mismatches (Details are
given in Table 2 of this manuscript and Figure D in the
Suppl. Methods of our previous publication [17]). Further
evaluation of the set of parameters used in the optimal
prediction model was also conducted (Table 3, Additional
file 1- Supp. Figure S1).
Step B3: modelling cross species hybridization with
biological experiments and sequence alignments
To predict human-mouse cross-hybridizations and further
redesign the probes, we optimize both the statistical mod-
els for biological measurement (biological Gold Standard -
GS) and the parameters used in the CSH theoretical
prediction models which are compared with the candidate
biological GSs in an iteratively optimal way [17]. Each
comparison results in an F-score (Equation 1 described
below after the Gold Standard) that balances the recall
(sensitivity) and precision and the CSH theoretical predic-
tion model with the largest F-score is selected. Here we
present, as an example, our procedure for identifying
mouse probes that are most likely to hybridize with
human RNAs, the converse would follow similar steps.
• CSH theoretical prediction models: Based on our
previously selected theoretical prediction models of
cross-hybridization [17] (Table 2, Model 1), we further
construct the BLAST prediction model based on the
total length of the sequence alignment and the admis-
sible maximum mismatches within the sequence, as
shown in Table 3. In order to balance recall and preci-
sion while identifying cross-hybridizing probes for
which the target gene requires a substitute SSP on the
H&M Array, the optimal set of BLAST predictions
(length of the alignments and the number of mis-
matches), are determined using the ideal F-Score while
systematically varying each parameter independently
(Additional file 1- Supp. Figure S2).
• Gold standards derived from the biological
experiments: We stratify the mouse probes exposed
to human RNAs according to their level of expression
in the biological array experiment (Table 1). For
H&M array version 1, using a dual channel experi-
mental design, the background adjusted absolute
CSH expression of probes (i.e. the raw, unmodified
expression of human probes when exposed to mouse
RNAs or the expression of mouse probes when
exposed to human RNAs), was stratified and alternate
GSs are produced accordingly. The optimal biological
GS is determined using relative high F-scores[17].
Since the single channel repeats of H&M Array
version 2 allow for the use of a relative ratio of aver-
age expression of cross species hybridization over
Table 2 Previously established definitions of four biological gold standards (GS) and the parameters of BLASTn results




GS1.x Top x ratio of relative expression (red/green) when exposed to erroneous RNA vs to correct RNA:
GS2.x* Top x% absolute expression when exposed to human RNA with mouse probes
GS3.x Top x% relative expression when exposed to human RNA with mouse probes (the expression of mouse probes when exposed to
human RNA divided by the expression when exposed to mouse RNA)
GS4.x The same as GS2 but absolute log2 based expression on both green channels of human and mouse RNA expression of mouse
probes > 4
Models Conditions and parameters
Model1* {18<Align≤20 and mis<5} U {20<Align≤ 30 and mis<6} U {30<Align≤40 and mis<7} U {40<Align≤50 and mis<8} U {50<Align and
mis<9}
Model2 {15 < Align ≤ 30 and mis < 2} U {30 < Align ≤ 40 and mis < 3} U {40 < Align ≤ 50 and mis < 5} U {50< Align and mis < 7}
Model3 Alig > 50 & mismatches < 6
Model4 score > 70 & Alig > 58 & mis < 6
Legend: biological GS: biological gold standard; CSH: cross-species hybridization; Align: alignment; mis: mismatch; U: union.
The Gold Standards used in the final design are annotated with an asterisks (*). These were selected by comparing the initial biological experimental data and
BLAST predictions using H&M array version 1.0 and details of this section are provided in our previous publication [17].
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species-specific expression after Variance Stabilization
Normalization (VSN) normalization[25], the optimal
biological GS was determined using both the relatively
higher F-scores and the absolute highest recall.
• Accuracy calculation: True positive CSH probes
were those that cross-species hybridized in the biologi-
cal GS and were also predicted by BLAST to do so.
False positives were those that were predicted by
BLAST but were not found in the GS. The precisions,
recalls (sensitivities) and F-scores (F) were calculated
for each theoretical model of cross-hybridization
against each biological GS at different thresholds of
biologically cross-hybridizing probes (Equation 1).
F = 2× precision× recall
precision + recall
(1)
• Identification of cross-hybridizing probes (Table 3):
Once the optimal set of BLAST prediction para-
meters and biological GSs were determined, all
probes from the GS that were considered as CSH
were tagged and new SSPs were designed - regardless
of whether they were predicted as cross-hybridizing
by BLAST. Additionally, probes were tagged for
future design when they did not have any expression
on the array and were predicted as cross-hybridising
using BLASTn program (Table 3: Model 1-1).
Step B4: probe redesign (green boxes in Figure 1)
I. Gene targets associated with cross species hybridizing
probes were identified for redesign. Transcripts (RefSeq
IDs) associated with each probe were identified from the
Agilent microarray annotation file (Additional file 1- Supp.
Table S1, resources 1-2). For those probes with a retired
Refseq or Unigene ID, the batch BLASTn program [24]
was used to retrieve the associated antisense Refseq or Uni-
gene sequences. The transcripts targeted by these probes
were downloaded from the NCBI GEO database via acces-
sion numbers GPL6840 and GPL7202.
II. New probes for the identified gene targets were
designed using the “GE Probe Design” program in the
Agilent eArray (Agilent, Santa Clara, CA) software. The
eArray parameters, that we used, include probe length
(60nt), probes per target (1), probe orientation (sense)
and design options ("best probe methodology” and
“design with 3’ bias”). These probes were further verified
computationally for cross-hybridization.
III. Newly designed probes were evaluated by the eAr-
ray “Probe Check” program using the built-in transcrip-
tome. The new candidate probes were retained if they
did not hybridize within their species with other targets
than the intended one nor across species with any other
transcripts. Otherwise, these candidate probes were
tagged as inappropriate and new probes were designed
for the intended target iteratively until they met these
criteria.
IV. All probes of the commercial arrays were retained,
while new probes were also added to the H&M array.
Annotation tables of cross species hybridization were
used as filters to identify the most SSP for each gene,
while the legacy probes were intended to allow for com-
parison of results with studies using the commercial
platforms.
Table 3 Definition of two sets of parameters used in the optimal CSH theoretical predictions for identification of CSH
probes.
Conditions Predicted # of CSH probes for vers.1
mouse probes




























Computational optimization results shown in Additional file 1 - Supp. Figure S1.
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Step B5: cross-hybridization experiment and extensive
annotation of the H&M array version 2
To validate the newly designed probes and extensively
annotate the H&M array version 2, a second biological
experiment was conducted by hybridizing all the probes
on the H&M array version 2 to three human melanoma
cell lines (MDA-MB-435) and three universal mouse
mRNAs. Six Samples (three with human RNA and three
with mouse RNA) were hybridized to the H&M array
version 2.0 (Table 1). The subsequent array scanning
and image processing followed the same procedure as
the initial biological experiment. Additionally, the back-
ground-subtracted expression measurements of six
arrays were normalized using VSN method [25] and
were log2 transformed. Human and mouse probe sets
were separately normalized to control for variation in
the proportion of human and mouse RNA across xeno-
graft replicates [16]. For each probe, the mean signal
intensity of the three biological replicates exposed to the
RNAs of the same species was used as the expression
value for that species. GS and BLAST parameter optimi-
zations were performed as described in Step 4 and in
our previous publication [17], and the propensity for
CSH of each probe was annotated (Dataset S1). This
extensive annotation of CSH was conducted by systema-
tically extending the threshold of the biological GS in
10% increments from 0% to 100% for all probes.
Stromal cell to cancer cell mRNA ratio estimation (Figure 1,
step C-1)
Housekeeping genes are typically constitutively expressed
genes required for the maintenance of basal cellular func-
tions, and are thus assumed to be stably expressed under
the same experimental conditions as well as between
human tissues and mouse tissues [22,23]. To estimate the
RNA expression ratio between human and mouse using
RNA quantity controlled H&M array experiments, the
expression value of human SSPs targeting human house-
keeping genes was divided by the expression value of
mouse SSPs targeting homologous housekeeping genes.
The SSPs satisfied the following four criteria: 1) they
were positively expressed (expressed intensity larger than
1, see Method: Step B1) across all samples when exposed
to the intended RNA, 2) among all probes for one spe-
cies, they expressed below a certain percentage of all
expression values when exposed to the RNA of the other
species, 3) they were not identified as CSH probes, and
4) were not theoretically predicted as CSH probes by the
BLASTn algorithm. For simplicity, a set of probes classi-
fied as “species-specific” in the 2nd criteria that passed
the threshold x are hereafter named “SSP x“. Different
thresholds were tested, and the optimal threshold was
selected according to the lowest variance of resulting
RNA ratios.
Stromal cell to cancer cell mRNA ratio and its validation
(Figure 1, step C-1)
Evaluation of the stromal cell to cancer cell mRNA ratio,
hereafter named as S/C ratio for simplicity, was indepen-
dently carried in two steps. The samples of the in vitro
biological experiments data for which the proportion of
mouse to human RNA is designed and known
(GSE23377) were used to validate the mouse to human
RNA ratio metric. This metric then serves as a proxy for
stroma to cancer cell RNA ratio in xenograft models con-
sisting of human cancer cell tumors harvested from mice
hosts.
Gene ontology enrichment of cross-species hybridizing
probes (Figure 1, step C-2) and visualization
After masking the top 5% of the most likely probes to
exhibit CSH, KEGG/GO enrichment analysis was
performed among the genes targeted by probes on the
custom array using the conditional hypergeometric test in
the Bioconductor GOStats package[26]. For comparison,
the same pathway/GO enrichment assessment was per-
formed on the commercial CSH probes, for the human
and mouse species separately. The resulting p-values were
adjusted for multiple testing by FDR[27] and pathways/
GO terms with less than 500 gene members were counted
[28]. Hexagon plots were conducted using the R package
hexbin with default parameters.
Results
Human tumor and mouse xenograft cross-species
hybridization of commercial arrays
Our previous study reported interspecies genetic differ-
ences and elucidated stromal microenvironment signals
from probes on human arrays unintentionally cross-
hybridizing with mouse homologous genes in xenograft
tumor models (Figures 1, 3, 4 in the publication [17]).
By identifying CSH probes from sequence alignment
and CSH experiment for the human whole-genome
arrays, deregulated stromal genes can be identified and
then their biological significance confirmed by the laser
capture microdissection of stromal cells from tumor
specimens [17]. In this study, within Agilent 44k whole
genome human arrays and mouse arrays, 4,259 commer-
cial probes (2,104 human, 2,155 mouse) pertaining to
3,550 distinct genes cross-hybridized above our optimal
threshold (highest 5% CSH) were annotated as cross-
species cross-hybridizing probes.
Design of the dual species H&M array
Using our computational cross-species hybridization algo-
rithms and the initial biologic experiment (Methods, 5%
threshold CSH), we identified 4,259 commercial probes as
cross-hybridizing (2,104 human, 2,155 mouse) corre-
sponding to 3,550 distinct genes. Therefore, we designed a
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custom 2x105k array (H&M array, Agilent custom plat-
form) combining all probes from both the human and
mouse Agilent 44k commercial whole genome arrays
(human: 41,000 probes; mouse: 41,174 probes). In addi-
tion, the H&M array contains new species-specific probes
we designed: 5.5k human and 5.2k mouse (Additional file
1- Supp. Table S2), covering 30k distinct human targets
and 32k mouse targets (Refseq IDs), respectively.
Analysis and annotation of the H&M arrays
A total of 87k probes were included on the H&M platform
version 1, containing all commercial human and mouse
probes, and 3,608 newly custom designed probes (Addi-
tional file 1- Supp. Table S2). Annotation for version 1 of
the array was conducted by comparing the results from
the initial in vitro biological experiment with the CSH the-
oretical predictions of probes on the H&M array. The
optimal biological GS of CSH as observed in the in vitro
experiments was defined by comparing the optimal CSH
theoretical prediction model with the most ideal para-
meters using a threshold of 18% for mouse probes [17]
and 20% for human probes. Meanwhile, the optimal para-
meters for BLASTn result interpretation were selected as
previously published (Figure D in Supplementary Methods
of our previous publication [17]), where the sequence
alignment derived from BLAST depended on the length of
the alignment (varying from 1 to 54) and the BLAST mis-
match number (varying from 1 to 12).
We further sought to incorporate theoretically predicted
and experimentally verified CSH probes to the array.
As illustrated in Figure 1 and Additional file 1- Supp.
Table S2, H&M array version 2 included 7.1k new custom
probes, containing 5k probes designed from experimen-
tally annotated CSH probes in version 1 of the platform,
in addition to 2.1k probes that the Agilent protocol sug-
gested as acceptable but whose theoretical prediction
resulted in CSH. Together with the 3.6k custom probes
designed in version1 array, the total 10.7k custom probes
covered 16% (5.3k) of human genes and 15% (5.1k) of
mouse genes (Additional file 1- Supp. Table S2). The set
of BLAST prediction parameters derived from the initial
in vitro biological experiment (Methods, step B3) per-
formed better in predicting CSH probes than a similar set
of parameters with shorter mismatch lengths (Methods,
step B2). Two GSs for CSH (Table 2: GS2 and GS3) per-
formed similarly in the initial in vitro experiment [17],
making it necessary to validate the initial experiment. We
found that biological GS3 that yielded a higher F-score
than biological GS2. The former used relative CSH expres-
sion values (i.e. the ratio of the absolute CSH expression
when exposed to the RNA of the other species compared
with the expression when exposed to the RNA of the
same species), while the latter used absolute CSH expres-
sion values due to the larger number of genes with
multiple probes in version 2 of the H&M array. A total of
4,644 probes on the H&M array (version 2) were anno-
tated as CSH, which comprised the top 5% relatively erro-
neously expressed (relative CSH) probes achieving the
highest recall when compared with CSH theoretical pre-
diction in Model 1-1 (Additional file 1- Supp. Table S2).
This threshold of 5% was derived from H&M array version
1 probes, as version 2 included all version 1 probes. The
estimated recall for mouse CSH probes was 25.6% (i.e.
25.6% probes were truly CSH among all annotated “CSH”
mouse probes) and precision was 13% (13% of all theoreti-
cally predicted CSH mouse probes are annotated by our
biological GS), while the annotated recall and precision
was 27% and 11%, respectively, for human CSH probes.
Additionally, our extensive annotation stratified all probes
on H&M array version 2 into ten levels according to their
probability of CSH, thus providing array users with more
flexibility to disregard CSH probes in their analyses.
Validation of H&M array version 1 annotation and
reduction of CSH
The reduction in CSH was further shown by an analyses
illustrated in Figure 2, which shows the comparison of
version 1 custom designed 3,292 human probes and
3,530 mouse probes (y-axis) with the pair-wise probes on
the Agilent commercial array (x-axis) for cross-species
expression using the validating biological experiment. In
contrast, when exposed to the RNA of the correct spe-
cies, there was no significant difference between custom
newly designed probes and the corresponding probes on
the Agilent 44k whole genome array (Figure 2, panels
C-D). Additionally, version 1 annotated CSH probes
were significantly over-represented among the version 2
annotated CSH probes (p < 2x10-16, OR = 3.3). Here, the
overlap between the annotated CSH probes demonstrates
the robustness of our design to identify the CSH probes
in a xenograft model.
Estimation of stromal cell to cancer cell mRNA ratio
In an in vitro validation experiment for stromal to cancer
cell ratio estimation, H&M arrays were separately
exposed to human and mouse RNAs (Table 1). The ratios
of the normalized expression between human SSPs and
mouse SSPs targeting homologous housekeeping genes
listed in Figure 3 were calculated.
As shown in Figure 3, the expression values of human
probes exposed to only human RNA were larger than
when exposed to only mouse RNA (Figure 3, panel A,
median ratio between human and mouse probes is 10.4),
and as shown in Panel B, the expression of mouse probes
exposed to only mouse RNA was larger than that when
exposed to only human RNA (median ratio between
mouse and human probes is 9.7). Changing the thresh-
olds to define an individual probe as species-specific
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(Method, Step C-1) to include from 10 to 50 pairs of
human and mouse SSPs provided a similar result, how-
ever the expression ratio between human and mouse
probes tended to be unchanged when all non-SSP were
included (data not shown). These results suggested that
the proportion of each species RNA can be estimated by
the species-specific human and mouse probes of the
pair-wise homologous housekeeping genes.
Stromal cells to cancer cell mRNA ratio (S/C ratio)
validation
Validations for our S/C ratio estimation was performed
with an in vitro biological experiment, where the stromal
cell proportions were controlled using known quantity of
RNAs as shown in Table 1. Using the in vitro CSH experi-
mental data, where two arrays containing both human and
mouse probes were exposed to equal quantities of human
and mouse RNAs (GSE23377), the ratios of 13 pairs of
homologous housekeeping gene expression were larger
than 10-fold when exposed to the intended RNA of one
species only (Figure 4, panels A,B), while was between 0
and 10 when exposed to an equal mix of human and
mouse RNAs simultaneously (Figure 4, panel C, Table 1).
The higher expression of mouse SSPs in panel B indicated
a better mouse RNA quality than human RNA.
GO and KEGG pathway enrichment analysis of cross-
species hybridizing probes
To control for CSH of probes in GO and KEGG path-
way enrichment analyses, we masked the 2,324 CSH
human probes on the custom H&M array, and observed
no KEGG pathways and only 1 GO molecular function
(RNA binding including more than 600 gene members)
significantly (FDR <5%) over-represented among the
44,144 human SSPs (targeting 30k Refseq IDs, 97%
coverage of Agilent whole human genome array). We
found no bias in GO or KEGG for the mouse probes of
the custom H&M array. Notably, gene ontology and
pathway biases exist among the CSH probes on com-
mercial single-species arrays, and should be accounted
for on-going and future xenograft tumor studies. Here
we are the first to report comprehensive analysis of
CSH probes between human cancer cells avoiding these
biases. We identified eight significantly enriched
(FDR<5%) KEGG pathways (seven human genes and
one mouse gene targeted only by CSH commercial
probes), eight GO molecular functions (all among
human genes), and conclusively, stromal functions
detected when using a dual species array for xenograft
tissues due to gene expression in mouse stromal tissues,
rather than in human cancer cells (data not shown).
Further, CSH probes confound the results of microarray
analyses of the metabolism pathway of xenobiotics by
cytochrome P450 when xenograft tumor models were
used due to the highly conserved nature of many
cytochrome P450 genes (data not shown). Using Agilent
44k human arrays, Sugawara et al. reported 28 genes
demonstrating higher induction in xenograft tumors
compared to the cells in culture medium[15]. Our inde-
pendent analysis revealed that 10 of these 28 previously
Figure 2 Comparison of expression of custom designed species-specific probes (Y axis) against the Commercial Agilent 44k array
probes (X axis). The log2 expression of custom species-specific probes (Y axis) was plotted against that of their Agilent counterpart targeting
the same gene (mean expression value, n = 3 arrays). The dashed diagonal corresponds to equal expression between the two types of probes.
The density distribution of the number of pairs of probes is shown as hexagons with increased color intensity. As shown in Panels A and B, the
human custom species-specific probes obtain a lower expression than their Agilent counterpart with mouse RNA and the similar results for mouse
probes (4.5 median fold reduction, 95% CI: 4.2, 4.9 for human probes; and 9.4 median fold reduction, 95% CI: 8.8, 10.3 for mouse probes; P <
2.2x10-16 for both; Non-parametric Mann-Whitney U tests). Panels C and D show that these species-specific probes of the H&M array perform as
well on average as those Agilent probes when exposed to the intended RNAs. Human-mouse gene cross-hybridization patterns we discovered
are provided in Dataset S1 (http://lussierlab.org/publications/HsMm_array).
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reported genes are targeted by commercial CSH probes
(data not shown). Additionally, we observed that the cyto-
chrome P450 pathway involved in xenobiotic metabolism
is enriched (cumulative hypergeometric pvalue = 1x10-5)
in the CSH probes found in the list of 28 genes (data not
shown), as would be expected for our xenograft model.
Other significant pathways and functions listed that
suggest relevant stromal functions include inflammatory
Figure 3 Species-specific probes of pair-wise human and mouse homologous housekeeping genes. The expression of 26 species specific
probes (SSPs) corresponding to 13 pairs of human and mouse homologous housekeeping genes (HK) are shown according to two experimental
conditions: exposure to the H&M array to Human RNA (X axis) or mouse RNA (Y axis). Each point is the mean expression value of 3 arrays and
the whiskers are the 95% confidential intervals (n = 6 arrays total). A median fold change for the 13 pairs of SSPs resulted in a 10.4 fold change
for human SSPs (panel A) and 9.7 fold change for mouse SSPs (panel B). Homologous genes utilised: RNASEH1, PMPCB, SFRS8, PRDX6, TRAPPC4,
MATR3, NIPA2, MRPL49, NOL7, VPS26A, HNRPDL, RPL39, OSBP.
Figure 4 Validation of cancer vs stromal RNA ratio using the expression of pair-wise human and mouse homologous housekeeping
genes measured by species-specific probes. The log2 expression ratio between human SSPs and mouse SSPs were plotted in three cases
using the initial experimental data, when probes were exposed to: A) only human RNAs, B) only mouse RNA, and C) both human and mouse
RNA. Consistent with the results shown in Figure 3, the expression ratios were larger than 10 (log2(10)=3.3, the dashed blue lines) when SSPs
were exposed to the indented RNA only, while the 75th quantile of expression ratios were between 0 and 10 when exposed to equally human
and mouse RNAs (panel C).
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signalling through the complement system, focal adhesion
and tight junctions involving transmembrane proteins
mediating intra-membrane and paracellular diffusion, as
well as motor activity and actin binding, and thus possibly
mediating invasion and metastasis processes. These results
indicated that the design of dual-species arrays and the
identification of CSH probes are critically important for
studies involving highly conserved genes and pathways in
xenograft models.
Discussion
We established that overlooking CSH probes in xeno-
graft models using commercial human arrays confound
incorrect attribution of deregulated stromal genes to
cancer cells. To increase the capability of analysing
molecular changes in the stromal compartment as well
as the interactions between cancer cells and reactive
tumor stroma in xenograft modelling, we designed the
first custom genome-wide human-mouse microarray,
and biologically validated it by observing an overall
reduction of the CSH (4.5 median fold reduction for
human probes; and 9.4 median fold reduction, for
mouse probes; p < 2x10-16, Mann-Whitney test). By
design, we select a framework of well-established com-
putational and biological methods to identify cross-
hybridizing probes, construct a cross-hybridizing map,
and identify new SSPs. Here, we provide a combined
description of the interplay between the computational
predictions of CSH of probes using BLASTn and obser-
vation of biological CSH that were utilized to develop
an approach stratifying probes in terms of their propen-
sities for cross-hybridization. We also implemented a
rigorous rationale for the selection of a threshold
needed to redesign the cross-hybridizing probes and
offer the foundational datasets used for conducting ana-
lyses over a dual-species array: a comprehensive map of
cross-hybridizations annotated with both sequence
alignment and biological data intended to increase the
accuracy and efficiency of measurements in tumor xeno-
graft models. Additionally, we developed a novel method
to estimate the mRNA ratio between mouse and human
mRNA as a cellularity ratio, thus providing an alterna-
tive to conventional histological counts of stroma vs.
cancer cells in xenograft models. Of note, the H&M
array could also be utilized in single species experi-
ments, as long as the probes of that species are selected.
This information is clearly available in the “species” col-
umn of Dataset S1. Further, for comparison of H&M
array results against previously published dataset using
single species commercial Agilent arrays, the H&M
probes corresponding to the commercial platforms are
annotated in the column “designer” of Dataset S1.
One limitation of the current study is that grouping all
of the stromal cell types into one category may be too
strong of a simplification of the complex cellularity of
the host tissue. For instance, changes in the presence of
certain types of stromal cells have profound effects on
the status of the tumor, and stromal cells are thought to
genomically “co-evolve” along with cancer cells during
tumor progression [29]. Also, the xenograft model
involves immune deficient mice, and therefore cannot
be used to understand much about the stromal immune
cells and associated pathways that participate in regu-
lating the tumor in the xenograft models. However,
xenograft models re-constituting bone marrow cells
from syngeneic donors may alleviate this limitation in
future studies. Further, with the advent of RNA-sequencing,
the utility of the present study may reside in our supple-
mental datasets that allow to reanalyze the species-
specific probes of commercial arrays for comparison with
RNA-seq experiments or to inform assembly algorithms
of RNA-seq in xenograft models. Another limitation is
that we have not considered non-coding RNAs in this
study.
Conclusion
There is ample indication that the issue of CSH is over-
looked in xenograft modelling, as the majority of tumor
xenograft studies utilize gene expression over human
arrays indiscriminately with no correction for homolo-
gous probes [30-35], leading to the incorrect attribution
of deregulated stromal genes to cancer cells. Further-
more, commercial human and mouse arrays are shown
to contain a large number CSH probes, suggesting that
commercial designs did not consider the potential reuse
of these arrays for xenograft modelling. While the
computational methods and biological validations are
straightforward and rely on well-established methods,
the originality of this study resides in (i) appropriately
computationally modelling the deceptively simple source
of CSH (homologous genes) - a problem that has none-
theless been overlooked by microarray corporations and
by many xenograft biologists in their array-related publi-
cations, in (ii) providing well-validated and novel work
products: a detailed cross-hybridization map of human
and mouse probes, as well as a cost-effective and super-
ior array for expression analyses of human xenograft
models, and in (iii) offering a new in silico metric for
estimating the cellularity ratio of cancer over stroma
that should in principle be applicable to RNAseq tran-
scriptomes as well. This study’s findings will improve
our capability of investigating and interpreting the inter-
actions between human cancer and mouse stromal cells
in xenograft modelling. Together, these technological
improvements will allow effective interrogation of
cancer cell-reactive stroma interactions during cancer
initiation, progression and response to therapeutic
interventions.
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